StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY) Reports Additional Top-Line Results from CYRAMZA Phase 3 RANGE Study
April 20, 2018 2:50 PM
Eli Lilly and Company (NYSE: LLY) today announced additional results from its global, randomized, double-blind, placebo-controlled Phase 3 RANGE ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Eli Lilly (LLY) PT Maintained at $95 at Cowen on 1Q18 Report; 'Top & Bottom Line Beat... FY18 Guidance Raised'
April 24, 2018 11:50 AM
Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mg
April 24, 2018 6:01 AM
Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
April 20, 2018 2:50 PM
